Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

One of the most important questions in obesity treatment is whether weight loss can be maintained over time. The SURMOUNT-4 trial by Aronne, Sattar, Horn, and colleagues, published in JAMA, specifically investigated the effects of continued versus discontinued tirzepatide treatment on long-term weight maintenance.

The randomized clinical trial enrolled adults with obesity who had achieved significant weight loss during an initial treatment period with tirzepatide. Participants were then randomized to either continue treatment or switch to placebo, allowing researchers to directly measure the impact of sustained therapy on weight maintenance.

The results clearly demonstrated that continued tirzepatide treatment successfully maintains substantial weight reduction, while those who discontinued therapy experienced significant weight regain. This finding establishes the importance of ongoing treatment for preserving the benefits of initial weight loss.

For patients and clinicians, this study provides critical guidance on treatment planning. Understanding that sustained tirzepatide therapy is key to maintaining weight loss helps set appropriate expectations and supports long-term treatment strategies that maximize the lasting health benefits of obesity management.